FDA Expands Its Import Alert on Olympus Endoscopes: What It Covers
On October 19 and 20, 2026, the U.S. Food and Drug Administration expanded an import alert covering certain Olympus devices made in Japan. The update added five models to the 58 the FDA first listed in June 2025, for 63 in all. It came less than two weeks after the FDA’s October 7 warning letter to Olympus, which we covered in a separate explainer. This article sticks to what the FDA and Olympus have published about the new action.
What an import alert does
An import alert directs the FDA to refuse entry to listed products at the U.S. border. It affects future shipments from the named facilities. It is not a recall, and by itself it does not require hospitals to stop using devices they already own.
What changed
The FDA updated its letter to health care providers on October 20 and said it continues to have concerns about outstanding violations of its Quality System regulation, despite extensive and ongoing efforts to address compliance issues. The update added these five models, effective October 20:
- the Endocapsule small intestinal capsule endoscope set (MAJ-2027)
- the Evis Exera II small intestinal videoscope (SIF-Q180)
- the Endoeye Flex deflectable videoscope (LTF-S190-10)
- two bronchovideoscopes (BF-1TH1100 and BF-H1100)
The addition broadened the alert to include enteroscopes and ingestible capsule imaging systems. In a notice on October 21, Olympus said the alert covers certain products made at three Japanese facilities: Hinode, Shirakawa and Aomori.
What the alert covers
Taken together with the June 2025 list, the alert now covers specific models in these categories, according to the FDA:
- ureterorenoscopes, used in the urinary tract
- bronchoscopes, used in the respiratory tract
- laparoscopes, used in the abdomen and pelvis
- enteroscopes, used in the small intestine
- ingestible capsule imaging systems, used to view the small bowel
- automated endoscope reprocessors, the machines that clean endoscopes between patients
What it does not cover
- Duodenoscopes. No duodenoscope appears in the FDA’s published list of models. The alert is separate from the duodenoscope infection issues at the center of the lawsuits.
- Related products. The FDA said the alert does not apply to replacement parts, connectors or single-use consumables used with the listed devices.
- Imports outside the U.S. Olympus said the alert does not currently affect imports into other countries.
- Devices already in service. The FDA said users may keep using listed devices that are already in use, as long as they are not having problems with them.
What the FDA told providers
The FDA’s recommendations to health care providers included these points:
- Follow the labeling and reprocessing instructions, including for accessory components.
- Do not use damaged devices or devices that have failed a leak test, because they could be a source of contamination.
- Set routine inspection and maintenance schedules in line with the manufacturer’s instructions.
- Be aware that some listed devices may have been recalled, and follow any recall notification letter.
- Discuss the benefits and risks of procedures with patients. The FDA said it does not recommend that procedures be canceled or delayed without that discussion.
- Report adverse events promptly.
What Olympus has said
Olympus said it does not expect the alerts to have a material impact on customers or an incremental effect on its consolidated financial results for the fiscal year ending March 31, 2027, and that its financial guidance is unchanged. It said products already in customers’ hands remain safe and effective when used according to their instructions for use, and that it is committed to working constructively with the FDA on the agency’s outstanding concerns.
What it means for patients
The alert concerns manufacturing quality and future shipments into the United States. It does not mean that any particular past procedure was unsafe. If you develop symptoms such as fever or chills after an endoscopic procedure, contact your health care provider promptly. Patients and providers can report problems with a device through the FDA’s MedWatch program.
How this relates to the lawsuits
Lawsuits over Olympus scope infections are being filed as individual product liability cases, and as of late October 2026 no multidistrict litigation had been consolidated. An import alert is a regulatory action. It does not decide any lawsuit, and whether a regulatory document matters in a particular case is a question for a lawyer reviewing that case. For the broader sequence of events, see our litigation timeline.
Sources
- FDA: Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan, Letter to Health Care Providers (October 20, 2026)
- Olympus: Notice Regarding Issuance of Import Alerts by FDA (October 21, 2026)
- MedTech Dive: FDA flags more Olympus safety problems in import block and warning letter (October 22, 2026)
- FDA: Warning Letter to Olympus Medical Systems Corporation, CMS #729208 (October 7, 2026)
Facts in this article come from the sources listed above and were current when the article was published or last updated. Statements about lawsuits describe allegations, which are claims and not findings by a court.
This article is general information, not medical or legal advice. Reading it does not create an attorney-client relationship. If you have symptoms of an infection, contact your health care provider. Attorney advertising. Prior results do not guarantee a similar outcome.